Köhler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975).
Google Scholar
Mullard, A. FDA approves 100th monoclonal antibody product. Nat. Rev. Drug Discov. 20, 491–495 (2021).
Google Scholar
Behring, E. V. & Kitasato, S. Über das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. Dtsch Med. Wochenschrift 49, 1113–1114 (1890).
Motley, M. P., Banerjee, K. & Fries, B. C. Monoclonal antibody-based therapies for bacterial infections. Curr. Opin. Infect. Dis. 32, 210–216 (2019).
Google Scholar
Raafat, D., Otto, M., Reppschläger, K., Iqbal, J. & Holtfreter, S. Fighting Staphylococcus aureus biofilms with monoclonal antibodies. Trends Microbiol. 27, 303–322 (2019).
Google Scholar
Hjelholt, A., Christiansen, G., Sørensen, U. S. & Birkelund, S. IgG subclass profiles in normal human sera of antibodies specific to five kinds of microbial antigens. Pathog. Dis. 67, 206–213 (2013).
Google Scholar
Bournazos, S., Corti, D., Virgin, H. W. & Ravetch, J. V. Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. Nature 588, 485–490 (2020).
Google Scholar
Kabanova, A. et al. Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proc. Natl Acad. Sci. USA 111, 17965–17970 (2014).
Google Scholar
Zheng, Q. et al. Viral neutralization by antibody-imposed physical disruption. Proc. Natl Acad. Sci. USA 116, 26933–26940 (2019).
Google Scholar
Hikmet, F. et al. The protein expression profile of ACE2 in human tissues. Mol. Syst. Biol. 16, e9610 (2020).
Google Scholar
Taylor, P. C. et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat. Rev. Immunol. 21, 382–393 (2021).
Google Scholar
Lu, L. L., Suscovich, T. J., Fortune, S. M. & Alter, G. Beyond binding: antibody effector functions in infectious diseases. Nat. Rev. Immunol. 18, 46–61 (2018).
Google Scholar
Winkler, E. S. et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell 184, 1804–1820.e16 (2021).
Google Scholar
Schäfer, A. et al. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J. Exp. Med. https://doi.org/10.1084/jem.20201993 (2021).
Case, J. B. et al. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Preprint at bioRxiv https://doi.org/10.1101/2022.03.17.484787 (2022).
Bournazos, S., Gupta, A. & Ravetch, J. V. The role of IgG Fc receptors in antibody-dependent enhancement. Nat. Rev. Immunol. 20, 633–643 (2020).
Google Scholar
Halstead, S. B. et al. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg. Infect. Dis. 8, 1474–1479 (2002).
Google Scholar
Dejnirattisai, W. et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328, 745–748 (2010).
Google Scholar
Beltramello, M. et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8, 271–283 (2010).
Google Scholar
Xu, L., Ma, Z., Li, Y., Pang, Z. & Xiao, S. in Advances in Immunology Vol. 151 (eds Frederick W. A. & Kenneth M. M.) 99–133 (Academic, 2021).
Mair-Jenkins, J. et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J. Infect. Dis. 211, 80–90 (2015).
Google Scholar
Casadevall, A., Dadachova, E. & Pirofski, L.-A. Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol. 2, 695–703 (2004).
Google Scholar
Hammarström, L., Marcotte, H., Piralla, A., Baldanti, F. & Pan-Hammarström, Q. Antibody therapy for COVID-19. Curr. Opin. Allergy Clin. Immunol. 21, 553–558 (2021).
Google Scholar
Simonovich, V. A. et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N. Engl. J. Med. 384, 619–629 (2021).
Google Scholar
Bégin, P. et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat. Med. 27, 2012–2024 (2021).
Google Scholar
Ray, Y. et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nat. Commun. 13, 383 (2022).
Google Scholar
McCafferty, J., Griffiths, A. D., Winter, G. & Chiswell, D. J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552–554 (1990).
Google Scholar
Hoogenboom, H. R. Overview of antibody phage-display technology and its applications. Methods Mol. Biol. 178, 1–37 (2002).
Google Scholar
Burton, D. R. et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024–1027 (1994).
Google Scholar
Ferrara, F. et al. A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies. Nat. Commun. 13, 462 (2022).
Google Scholar
Maynard, J. A. et al. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat. Biotechnol. 20, 597–601 (2002).
Google Scholar
Burkovitz, A. & Ofran, Y. Understanding differences between synthetic and natural antibodies can help improve antibody engineering. mAbs 8, 278–287 (2016).
Google Scholar
Novobrantseva, T. et al. Stochastic pairing of Ig heavy and light chains frequently generates B cell antigen receptors that are subject to editing in vivo. Int. Immunol. 17, 343–350 (2005).
Google Scholar
Tiegs, S. L., Russell, D. M. & Nemazee, D. Receptor editing in self-reactive bone marrow B cells. J. Exp. Med. 177, 1009–1020 (1993).
Google Scholar
Gay, D., Saunders, T., Camper, S. & Weigert, M. Receptor editing: an approach by autoreactive B cells to escape tolerance. J. Exp. Med. 177, 999–1008 (1993).
Google Scholar
Norris, M. H. & Blackburn, J. K. Raxibacumab: a panacea for anthrax disease? Lancet Infect. Dis. 20, 886–887 (2020).
Pedrioli, A. & Oxenius, A. Single B cell technologies for monoclonal antibody discovery. Trends Immunol. 42, 1143–1158 (2021).
Google Scholar
Klein, U., Küppers, R. & Rajewsky, K. Variable region gene analysis of B cell subsets derived from a 4-year-old child: somatically mutated memory B cells accumulate in the peripheral blood already at young age. J. Exp. Med. 180, 1383–1393 (1994).
Google Scholar
Lee, E. C. et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nat. Biotechnol. 32, 356–363 (2014).
Google Scholar
Scheid, J. F. et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458, 636–640 (2009).
Google Scholar
Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856–861 (2010).
Google Scholar
Huang, J. et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406–412 (2012).
Google Scholar
Kong, L. et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 20, 796–803 (2013).
Google Scholar
Mascola, J. R. et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73, 4009–4018 (1999).
Google Scholar
Moldt, B. et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl Acad. Sci. USA 109, 18921–18925 (2012).
Google Scholar
Wang, Q. et al. A combination of human broadly neutralizing antibodies against hepatitis B virus HBsAg with distinct epitopes suppresses escape mutations. Cell Host Microbe 28, 335–349.e6 (2020).
Google Scholar
Hartley, G. E. et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci. Immunol. 5, eabf8891 (2020).
Google Scholar
Macagno, A. et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J. Virol. 84, 1005–1013 (2010).
Google Scholar
McCoy, L. E. & Burton, D. R. Identification and specificity of broadly neutralizing antibodies against HIV. Immunol. Rev. 275, 11–20 (2017).
Google Scholar
Kwakkenbos, M. J. et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat. Med. 16, 123–128 (2010).
Google Scholar
Traggiai, E. et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 10, 871–875 (2004).
Google Scholar
Steinitz, M., Klein, G., Koskimies, S. & Makel, O. EB virus-induced B lymphocyte cell lines producing specific antibody. Nature 269, 420–422 (1977).
Google Scholar
Corti, D. & Lanzavecchia, A. Efficient methods to isolate human monoclonal antibodies from memory B cells and plasma cells. Microbiol. Spectr. https://doi.org/10.1128/microbiolspec.AID-0018-2014 (2014).
Kuraoka, M. et al. Complex antigens drive permissive clonal selection in germinal centers. Immunity 44, 542–552 (2016).
Google Scholar
Su, K.-Y., Watanabe, A., Yeh, C.-H., Kelsoe, G. & Kuraoka, M. Efficient culture of human naive and memory B cells for use as APCs. J. Immunol. 197, 4163–4176 (2016).
Google Scholar
Luo, X. M. et al. Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. Blood 113, 1422–1431 (2009).
Google Scholar
McCarthy, K. R. et al. Memory B cells that cross-react with group 1 and group 2 influenza A viruses are abundant in adult human repertoires. Immunity 48, 174–184.e9 (2018).
Google Scholar
Lindner, J. M. et al. Human memory B cells harbor diverse cross-neutralizing antibodies against BK and JC polyomaviruses. Immunity 50, 668–676.e5 (2019).
Google Scholar
Wagar, L. E. et al. Modeling human adaptive immune responses with tonsil organoids. Nat. Med. 27, 125–135 (2021).
Google Scholar
Tanno, H. et al. A facile technology for the high-throughput sequencing of the paired VH:VL and TCRβ:TCRα repertoires. Sci. Adv. 6, eaay9093 (2020).
Google Scholar
DeKosky, B. J. et al. In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire. Nat. Med. 21, 86–91 (2015).
Google Scholar
Chen, D. et al. Coupled analysis of transcriptome and BCR mutations reveals role of OXPHOS in affinity maturation. Nat. Immunol. 22, 904–913 (2021).
Google Scholar
Thompson, E. A. et al. Metabolic programs define dysfunctional immune responses in severe COVID-19 patients. Cell Rep. 34, 108863 (2021).
Google Scholar
Buus, T. B. et al. Improving oligo-conjugated antibody signal in multimodal single-cell analysis. eLife https://doi.org/10.7554/eLife.61973 (2021).
Ramaswamy, A. et al. Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children. Immunity 54, 1083–1095.e7 (2021).
Google Scholar
Lavinder, J. J., Horton, A. P., Georgiou, G. & Ippolito, G. C. Next-generation sequencing and protein mass spectrometry for the comprehensive analysis of human cellular and serum antibody repertoires. Curr. Opin. Chem. Biol. 24, 112–120 (2015).
Google Scholar
Georgiou, G. et al. The promise and challenge of high-throughput sequencing of the antibody repertoire. Nat. Biotechnol. 32, 158–168 (2014).
Google Scholar
Use of Convalescent Whole Blood or Plasma Collected from Patients Recovered from Ebola Virus Disease for Transfusion, as an Empirical Treatment during Outbreaks: Interim Guidance for National Health Authorities and Blood Transfusion Services Version 1.0 (World Health Organization, 2014).
Setliff, I. et al. High-throughput mapping of B cell receptor sequences to antigen specificity. Cell 179, 1636–1646.e15 (2019).
Google Scholar
Finn, J. A. et al. Identification of structurally related antibodies in antibody sequence databases using rosetta-derived position-specific scoring. Structure 28, 1124–1130.e5 (2020).
Google Scholar
Sevy, A. M. et al. Computationally designed cyclic peptides derived from an antibody loop increase breadth of binding for influenza variants. Structure 28, 1114–1123.e4 (2020).
Google Scholar
Foglierini, M., Pappas, L., Lanzavecchia, A., Corti, D. & Perez, L. AncesTree: an interactive immunoglobulin lineage tree visualizer. PLoS Comput. Biol. 16, e1007731 (2020).
Google Scholar
Kramer, K. J. et al. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. Cell Rep. 37, 109784 (2021).
Google Scholar
Lund, J. et al. Human FcγRI and FcγRII interact with distinct but overlapping sites on human IgG. J. Immunol. 147, 2657–2662 (1991).
Google Scholar
Lee, W. S., Wheatley, A. K., Kent, S. J. & DeKosky, B. J. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat. Microbiol. 5, 1185–1191 (2020).
Google Scholar
Loo, Y.-M. et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Sci. Transl Med. 14, eabl8124 (2022).
Google Scholar
Oganesyan, V., Gao, C., Shirinian, L., Wu, H. & Dall’Acqua, W. F. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr. Sect. D. 64, 700–704 (2008).
Google Scholar
Gupta, A. et al. Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N. Engl. J. Med. 385, 1941–1950 (2021).
Google Scholar
Weitzenfeld, P., Bournazos, S. & Ravetch, J. V. Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways. J. Clin. Invest. 129, 3952–3962 (2019).
Google Scholar
Grobben, M., Stuart, R. A. & van Gils, M. J. The potential of engineered antibodies for HIV-1 therapy and cure. Curr. Opin. Virol. 38, 70–80 (2019).
Google Scholar
Gaudinski, M. R. et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults. PLoS Med. 15, e1002493 (2018).
Google Scholar
Rudicell, R. S. et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J. Virol. 88, 12669–12682 (2014).
Google Scholar
Julien, J.-P. et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog. 9, e1003342 (2013).
Google Scholar
Dall’Acqua, W. F., Kiener, P. A. & Wu, H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem. 281, 23514–23524 (2006).
Google Scholar
Griffin, M. P. et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N. Engl. J. Med. 383, 415–425 (2020).
Google Scholar
Hammitt, L. L. et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N. Engl. J. Med. 386, 837–846 (2022).
Google Scholar
Domachowske, J. B. et al. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatr. Infect. Dis. J. 37, 886–892 (2018).
Google Scholar
Labrijn, A. F., Janmaat, M. L., Reichert, J. M. & Parren, P. W. H. I. Bispecific antibodies: a mechanistic review of the pipeline. Nat. Rev. Drug Discov. 18, 585–608 (2019).
Google Scholar
Wec, A. Z. et al. A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses. Science 354, 350–354 (2016).
Google Scholar
Bournazos, S., Gazumyan, A., Seaman, M. S., Nussenzweig, M. C. & Ravetch, J. V. Bispecific anti-HIV-1 antibodies with enhanced breadth and potency. Cell 165, 1609–1620 (2016).
Google Scholar
Xu, L. et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science 358, 85–90 (2017).
Google Scholar
Muyldermans, S. Nanobodies: natural single-domain antibodies. Annu. Rev. Biochem. 82, 775–797 (2013).
Google Scholar
Scully, M. et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N. Engl. J. Med. 380, 335–346 (2019).
Google Scholar
Xu, J. et al. Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. Nature 595, 278–282 (2021).
Google Scholar
Plückthun, A. Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu. Rev. Pharmacol. Toxicol. 55, 489–511 (2015).
Google Scholar
Rothenberger, S. et al. Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants. Preprint at bioRxiv https://doi.org/10.1101/2021.02.03.429164 (2022).
Walser, M. et al. Highly potent anti-SARS-CoV-2 multivalent DARPin therapeutic candidates. Preprint at bioRxiv https://doi.org/10.1101/2020.08.25.256339 (2021).
DARPins stack up as anti-COVID-19 agents. Nat. Biotechnol. 38, 1369–1369 (2020).
Su, S. et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 24, 490–502 (2016).
Google Scholar
V’kovski, P., Kratzel, A., Steiner, S., Stalder, H. & Thiel, V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 19, 155–170 (2021).
Google Scholar
Killerby, M. E. et al. Human coronavirus circulation in the United States 2014–2017. J. Clin. Virol. 101, 52–56 (2018).
Google Scholar
Olsen, S. J. et al. Transmission of the severe acute respiratory syndrome on aircraft. N. Engl. J. Med. 349, 2416–2422 (2003).
Google Scholar
Yount, B. et al. Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc. Natl Acad. Sci. USA 100, 12995–13000 (2003).
Google Scholar
Cauchemez, S. et al. Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility. Lancet Infect. Dis. 14, 50–56 (2014).
Google Scholar
Graham, R. L., Donaldson, E. F. & Baric, R. S. A decade after SARS: strategies for controlling emerging coronaviruses. Nat. Rev. Microbiol. 11, 836–848 (2013).
Google Scholar
Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020).
Google Scholar
Chan, J. F. et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395, 514–523 (2020).
Google Scholar
Coronavirus disease (COVID-19) pandemic. World Health Organization https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (2021).
Raj, V. S. et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495, 251–254 (2013).
Google Scholar
Harrison, S. C. Viral membrane fusion. Virology 479-480, 498–507 (2015).
Google Scholar
Park, Y.-J. et al. Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors. Nat. Struct. Mol. Biol. 26, 1151–1157 (2019).
Google Scholar
Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).
Google Scholar
Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221–224 (2020).
Google Scholar
Cai, Y. et al. Distinct conformational states of SARS-CoV-2 spike protein. Science 369, 1586–1592 (2020).
Google Scholar
Tripp, R. A. et al. Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins. J. Virol. Meth. 128, 21–28 (2005).
Google Scholar
Jiang, L. et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci. Transl. Med. 6, 234ra259–234ra259 (2014).
Google Scholar
An EUA for sotrovimab for treatment of COVID-19. Med. Lett. Drugs Ther. 63, 97-xx98 (2021).
Baum, A. et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science 370, 1110–1115 (2020).
Google Scholar
Baum, A. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 369, 1014–1018 (2020).
Google Scholar
Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010–1014 (2020).
Google Scholar
Deeks, E. D. Casirivimab/Imdevimab: first approval. Drugs 81, 2047–2055 (2021).
Google Scholar
Jones, B. E. et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.abf1906 (2021).
Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120–124 (2020).
Google Scholar
Dougan, M. et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. N. Engl. J. Med. 385, 1382–1392 (2021).
Google Scholar
Gottlieb, R. L. et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA 325, 632–644 (2021).
Google Scholar
Dong, J. et al. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nat. Microbiol. 6, 1233–1244 (2021).
Google Scholar
Zost, S. J. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443–449 (2020).
Google Scholar
Tixagevimab and cilgavimab (Evusheld) for pre-exposure prophylaxis of COVID-19. JAMA 327, 384–385 (2022).
Google Scholar
Li, T. et al. Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants. Nat. Commun. 12, 5652 (2021).
Google Scholar
Ryu, D.-K. et al. Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant. Biochem. Biophys. Res. Commun. 566, 135–140 (2021).
Google Scholar
Westendorf, K. et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 39, 110812 (2022).
Google Scholar
Hoffmann, M. et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell 185, 447–456.e11 (2022).
Google Scholar
Fenwick, C. et al. SARS-CoV-2 Omicron potently neutralized by a novel antibody with unique spike binding properties. Preprint at bioRxiv https://doi.org/10.1101/2022.03.18.484873 (2022).
Du, S. et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell 183, 1013–1023.e13 (2020).
Google Scholar
Tortorici, M. A. et al. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science 370, 950–957 (2020).
Google Scholar
Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 369, 643–650 (2020).
Google Scholar
Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682–687 (2020).
Google Scholar
Fenwick, C. et al. A highly potent antibody effective against SARS-CoV-2 variants of concern. Cell Rep. 37, 109814 (2021).
Google Scholar
Wu, N. C. et al. An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain. Cell Rep. 33, 108274 (2020).
Google Scholar
Liu, L. et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584, 450–456 (2020).
Google Scholar
Kreye, J. et al. A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model. Cell 183, 1058–1069.e19 (2020).
Google Scholar
Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115–119 (2020).
Google Scholar
Tian, X. et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg. Microbes Infect. 9, 382–385 (2020).
Google Scholar
Zhou, D. et al. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nat. Struct. Mol. Biol. 27, 950–958 (2020).
Google Scholar
Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290–295 (2020).
Google Scholar
Cerutti, G. et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe 29, 819–833.e7 (2021).
Google Scholar
McCallum, M. et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell 184, 2332–2347.e16 (2021).
Google Scholar
Suryadevara, N. et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell 184, 2316–2331.e15 (2021).
Google Scholar
Chi, X. et al. A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2. Science 369, 650–655 (2020).
Google Scholar
Shrock, E. et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science https://doi.org/10.1126/science.abd4250 (2020).
Pinto, D. et al. Broad betacoronavirus neutralization by a stem helix-specific human antibody. Science 373, 1109–1116 (2021).
Google Scholar
O’Brien, M. P. et al. Subcutaneous REGEN-COV antibody combination to prevent COVID-19. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2109682 (2021).
Arvin, A. M. et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature 584, 353–363 (2020).
Google Scholar
Battles, M. B. & McLellan, J. S. Respiratory syncytial virus entry and how to block it. Nat. Rev. Microbiol. 17, 233–245 (2019).
Google Scholar
Glezen, W. P., Taber, L. H., Frank, A. L. & Kasel, J. A. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140, 543–546 (1986).
Google Scholar
Hall, C. B., Walsh, E. E., Long, C. E. & Schnabel, K. C. Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163, 693–698 (1991).
Google Scholar
American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn. Respiratory syncytial virus immune globulin intravenous: indications for use. Pediatrics 99, 645–650 (1997).
Groothuis, J. R. et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N. Engl. J. Med. 329, 1524–1530 (1993).
Google Scholar
Group, T. I.-R. S. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102, 531–537 (1998).
Google Scholar
Magro, M. et al. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc. Natl Acad. Sci. USA 109, 3089–3094 (2012).
Google Scholar
Ngwuta, J. O. et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci. Transl. Med. 7, 309ra162 (2015).
Google Scholar
Huang, K., Incognito, L., Cheng, X., Ulbrandt, N. D. & Wu, H. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J. Virol. 84, 8132–8140 (2010).
Google Scholar
McLellan, J. S. et al. Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat. Struct. Mol. Biol. 17, 248–250 (2010).
Google Scholar
Carbonell-Estrany, X. et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 125, e35–e51 (2010).
Google Scholar
Kwakkenbos, M. J. et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat. Med. 16, 123–128 (2010).
Google Scholar
McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592–598 (2013).
Google Scholar
Tian, D. et al. Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. Nat. Commun. 8, 1877 (2017).
Google Scholar
Sivapalasingam, S. et al. Phase 1 study evaluating safety, tolerability, pharmacokinetics and immunogenicity of REGN2222 in healthy adults: a new human monoclonal RSV-F antibody for RSV prevention. Open Forum Infect. Dis. https://doi.org/10.1093/ofid/ofv133.628 (2015).
Simões, E. A. F. et al. Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa951 (2020).
Malvy, D., McElroy, A. K., de Clerck, H., Günther, S. & van Griensven, J. Ebola virus disease. Lancet 393, 936–948 (2019).
Google Scholar
Lee, J. E. et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454, 177–182 (2008).
Google Scholar
Côté, M. et al. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477, 344–348 (2011).
Google Scholar
Olal, D. et al. Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus. J. Virol. 86, 2809–2816 (2012).
Google Scholar
Wilson, J. A. et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287, 1664–1666 (2000).
Google Scholar
Qiu, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47–53 (2014).
Google Scholar
Corti, D. et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351, 1339–1342 (2016).
Google Scholar
Misasi, J. et al. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science 351, 1343–1346 (2016).
Google Scholar
Pascal, K. E. et al. Development of clinical-stage human monoclonal antibodies that treat advanced Ebola virus disease in nonhuman primates. J. Infect. Dis. 218, S612–s626 (2018).
Google Scholar
Mulangu, S. et al. A randomized, controlled trial of Ebola virus disease therapeutics. N. Engl. J. Med. 381, 2293–2303 (2019).
Google Scholar
Markham, A. REGN-EB3: first approval. Drugs 81, 175–178 (2021).
Google Scholar
Lee, A. Ansuvimab: first approval. Drugs 81, 595–598 (2021).
Google Scholar
Griffiths, P. & Reeves, M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat. Rev. Microbiol. https://doi.org/10.1038/s41579-021-00582-z (2021).
Schleiss, M. R. Congenital cytomegalovirus: impact on child health. Contemp. Pediatr. 35, 16–24 (2018).
Google Scholar
Ciferri, C. et al. Structural and biochemical studies of HCMV gH/gL/gO and Pentamer reveal mutually exclusive cell entry complexes. Proc. Natl Acad. Sci. USA 112, 1767–1772 (2015).
Google Scholar
Foglierini, M., Marcandalli, J. & Perez, L. HCMV envelope glycoprotein diversity demystified. Front. Microbiol. 10, 1005 (2019).
Google Scholar
Kabanova, A. et al. Platelet-derived growth factor-α receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer. Nat. Microbiol. 1, 16082 (2016).
Google Scholar
Kschonsak, M. et al. Structures of HCMV Trimer reveal the basis for receptor recognition and cell entry. Cell 184, 1232–1244.e16 (2021).
Google Scholar
Martinez-Martin, N. et al. An unbiased screen for human cytomegalovirus identifies Neuropilin-2 as a central viral receptor. Cell https://doi.org/10.1016/j.cell.2018.06.028 (2018).
Kschonsak, M. et al. Structural basis for HCMV Pentamer receptor recognition and antibody neutralization. Sci. Adv. 8, eabm2536 (2022).
Google Scholar
Wrapp, D. et al. Structural basis for HCMV Pentamer recognition by neuropilin 2 and neutralizing antibodies. Sci. Adv. 8, eabm2546 (2022).
Google Scholar
Wille, P. T., Wisner, T. W., Ryckman, B. & Johnson, D. C. Human cytomegalovirus (HCMV) glycoprotein gB promotes virus entry in trans acting as the viral fusion protein rather than as a receptor-binding protein. MBio 4, e00332–00313 (2013).
Google Scholar
Burke, H. G. & Heldwein, E. E. Crystal structure of the human cytomegalovirus glycoprotein B. PLoS Pathog. 11, e1005227 (2015).
Google Scholar
Chandramouli, S. et al. Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody. Nat. Commun. 6, 8176 (2015).
Google Scholar
Perotti, M., Marcandalli, J., Demurtas, D., Sallusto, F. & Perez, L. Rationally designed human cytomegalovirus gB nanoparticle vaccine with improved immunogenicity. PLoS Pathog. 16, e1009169 (2020).
Google Scholar
Gabanti, E. et al. Early T cell reconstitution and cytokine profile may help to guide a personalized management of human cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. J. Clin. Virol. 135, 104734 (2021).
Google Scholar
Baldanti, F., Lilleri, D. & Gerna, G. Monitoring human cytomegalovirus infection in transplant recipients. J. Clin. Virol. 41, 237–241 (2008).
Google Scholar
Fouts, A. E. et al. Mechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109. Proc. Natl Acad. Sci. USA 111, 8209–8214 (2014).
Google Scholar
Jabs, D. A. et al. HIV and cytomegalovirus viral load and clinical outcomes in AIDS and cytomegalovirus retinitis patients: monoclonal antibody cytomegalovirus retinitis trial. AIDS 16, 877–887 (2002).
Google Scholar
Ishida, J. H. et al. Phase 1 randomized, double-blind, placebo-controlled study of RG7667, an anticytomegalovirus combination monoclonal antibody therapy, in healthy adults. Antimicrob. Agents Chemother. 59, 4919–4929 (2015).
Google Scholar
Ishida, J. H. et al. Phase 2 randomized, double-blind, placebo-controlled trial of RG7667, a combination monoclonal antibody, for prevention of cytomegalovirus infection in high-risk kidney transplant recipients. Antimicrob. Agents Chemother. https://doi.org/10.1128/aac.01794-16 (2017).
Patel, H. D. et al. In vitro characterization of human cytomegalovirus-targeting therapeutic monoclonal antibodies LJP538 and LJP539. Antimicrob. Agents Chemother. 60, 4961–4971 (2016).
Google Scholar
Maertens, J. et al. Phase 2 study of anti-human cytomegalovirus monoclonal antibodies for prophylaxis in hematopoietic cell transplantation. Antimicrob. Agents Chemother. https://doi.org/10.1128/aac.02467-19 (2020).
Nelson, C. S. et al. Preexisting antibodies can protect against congenital cytomegalovirus infection in monkeys. JCI Insight https://doi.org/10.1172/jci.insight.94002 (2017).
Revello, M. G. et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N. Engl. J. Med. 370, 1316–1326 (2014).
Google Scholar
Spinillo, A. & Gerna, G. Hyperimmune globulin to prevent congenital CMV infection. N. Engl. J. Med. 370, 2544–2545 (2014).
Google Scholar
Yamayoshi, S. & Kawaoka, Y. Current and future influenza vaccines. Nat. Med. 25, 212–220 (2019).
Google Scholar
Jones, J. E. et al. Parallel evolution between genomic segments of seasonal human influenza viruses reveals RNA-RNA relationships. eLife https://doi.org/10.7554/eLife.66525 (2021).
Zost, S. J., Wu, N. C., Hensley, S. E. & Wilson, I. A. Immunodominance and antigenic variation of influenza virus hemagglutinin: implications for design of universal vaccine immunogens. J. Infect. Dis. 219, S38–S45 (2019).
Google Scholar
Virk, R. K. et al. Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity. Proc. Natl Acad. Sci. USA 117, 619–628 (2020).
Google Scholar
Wang, C.-C. et al. Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc. Natl Acad. Sci. USA 106, 18137–18142 (2009).
Google Scholar
Wu, N. C. & Wilson, I. A. Structural insights into the design of novel anti-influenza therapies. Nat. Struct. Mol. Biol. 25, 115–121 (2018).
Google Scholar
Krammer, F. The human antibody response to influenza A virus infection and vaccination. Nat. Rev. Immunol. 19, 383–397 (2019).
Google Scholar
Tzarum, N. et al. Structure and receptor binding of the hemagglutinin from a human H6N1 influenza virus. Cell Host Microbe 17, 369–376 (2015).
Google Scholar
Cheung, C. S. et al. Identification and structure of a multidonor class of head-directed influenza-neutralizing antibodies reveal the mechanism for its recurrent elicitation. Cell Rep. 32, 108088 (2020).
Google Scholar
Ekiert, D. C. et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489, 526–532 (2012).
Google Scholar
Lee, P. S. et al. Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc. Natl Acad. Sci. USA 109, 17040–17045 (2012).
Google Scholar
Lee, P. S. et al. Receptor mimicry by antibody F045–092 facilitates universal binding to the H3 subtype of influenza virus. Nat. Commun. 5, 3614 (2014).
Google Scholar
Bajic, G. et al. Influenza antigen engineering focuses immune responses to a subdominant but broadly protective viral epitope. Cell Host Microbe 25, 827–835.e6 (2019).
Google Scholar
Bangaru, S. et al. A site of vulnerability on the influenza virus hemagglutinin head domain trimer interface. Cell 177, 1136–1152.e18 (2019).
Google Scholar
Yassine, H. M. et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. 21, 1065–1070 (2015).
Google Scholar
Wei, C. J. et al. Next-generation influenza vaccines: opportunities and challenges. Nat. Rev. Drug Discov. 19, 239–252 (2020).
Google Scholar
Harshbarger, W. D. et al. Unique structural solution from a V(H)3-30 antibody targeting the hemagglutinin stem of influenza A viruses. Nat. Commun. 12, 559 (2021).
Google Scholar
He, W. et al. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc. Natl Acad. Sci. USA 113, 11931–11936 (2016).
Google Scholar
Sui, J. et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16, 265–273 (2009).
Google Scholar
Throsby, M. et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 3, e3942 (2008).
Google Scholar
Ekiert, D. C. et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333, 843–850 (2011).
Google Scholar
Friesen, R. H. et al. A common solution to group 2 influenza virus neutralization. Proc. Natl Acad. Sci. USA 111, 445–450 (2014).
Google Scholar
Giang, E. et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc. Natl Acad. Sci. USA 109, 6205–6210 (2012).
Google Scholar
Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850–856 (2011).
Google Scholar
Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. Science 337, 1343–1348 (2012).
Google Scholar
Nakamura, G. et al. An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell Host Microbe 14, 93–103 (2013).
Google Scholar
Kallewaard, N. L. et al. Structure and function analysis of an antibody recognizing all influenza A subtypes. Cell 166, 596–608 (2016).
Google Scholar
Impagliazzo, A. et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349, 1301–1306 (2015).
Google Scholar
Ali, S. O. et al. Evaluation of MEDI8852, an anti-influenza A monoclonal antibody, in treating acute uncomplicated influenza. Antimicrob. Agents Chemother. https://doi.org/10.1128/aac.00694-18 (2018).
Stern, A. M. & Markel, H. The history of vaccines and immunization: familiar patterns, new challenges. Health Aff. 24, 611–621 (2005).
Google Scholar
Burton, D. R. What are the most powerful immunogen design vaccine strategies? Reverse vaccinology 2.0 shows great promise. Cold Spring Harb. Perspect. Biol. https://doi.org/10.1101/cshperspect.a030262 (2017).
Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccin. Immunol. 17, 1055–1065 (2010).
Google Scholar
Malito, E., Carfi, A. & Bottomley, M. J. Protein crystallography in vaccine research and development. Int. J. Mol. Sci. 16, 13106–13140 (2015).
Google Scholar
Lanzavecchia, A., Frühwirth, A., Perez, L. & Corti, D. Antibody-guided vaccine design: identification of protective epitopes. Curr. Opin. Immunol. 41, 62–67 (2016).
Google Scholar
Wilson, P. C. & Andrews, S. F. Tools to therapeutically harness the human antibody response. Nat. Rev. Immunol. 12, 709–719 (2012).
Google Scholar
Pantophlet, R. & Burton, D. R. Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies. Trends Mol. Med. 9, 468–473 (2003).
Google Scholar
Sesterhenn, F., Bonet, J. & Correia, B. E. Structure-based immunogen design-leading the way to the new age of precision vaccines. Curr. Opin. Struct. Biol. 51, 163–169 (2018).
Google Scholar
Gilman, M. S. et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci. Immunol. https://doi.org/10.1126/sciimmunol.aaj1879 (2016).
Boyington, J. C. et al. Structure-based design of head-only fusion glycoprotein immunogens for respiratory syncytial virus. PLOS ONE 11, e0159709 (2016).
Google Scholar
Krarup, A. et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat. Commun. 6, 8143 (2015).
Google Scholar
Joyce, M. G. et al. Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat. Struct. Mol. Biol. 23, 811–820 (2016).
Google Scholar
Liljeroos, L., Malito, E., Ferlenghi, I. & Bottomley, M. J. Structural and computational biology in the design of immunogenic vaccine antigens. J. Immunol. Res. 2015, 156241 (2015).
Google Scholar
Correia, B. E. et al. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 18, 1116–1126 (2010).
Google Scholar
Ofek, G. et al. Elicitation of structure-specific antibodies by epitope scaffolds. Proc. Natl Acad. Sci. USA 107, 17880–17887 (2010).
Google Scholar
Guenaga, J. et al. Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS ONE 6, e16074 (2011).
Google Scholar
Azoitei, M. L. et al. Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope. J. Mol. Biol. 415, 175–192 (2012).
Google Scholar
Kuhlman, B. & Bradley, P. Advances in protein structure prediction and design. Nat. Rev. Mol. Cell Biol. 20, 681–697 (2019).
Google Scholar
McLellan, J. S. et al. Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J. Mol. Biol. 409, 853–866 (2011).
Google Scholar
Correia, B. E. et al. Proof of principle for epitope-focused vaccine design. Nature 507, 201–206 (2014).
Google Scholar
Sesterhenn, F. et al. Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen. PLoS Biol. 17, e3000164 (2019).
Google Scholar
Sesterhenn, F. et al. De novo protein design enables the precise induction of RSV-neutralizing antibodies. Science https://doi.org/10.1126/science.aay5051 (2020).
Azoitei, M. L. et al. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science 334, 373–376 (2011).
Google Scholar
Rubinstein, N. D. et al. Computational characterization of B-cell epitopes. Mol. Immunol. 45, 3477–3489 (2008).
Google Scholar
Jin, L., Fendly, B. M. & Wells, J. A. High resolution functional analysis of antibody-antigen interactions. J. Mol. Biol. 226, 851–865 (1992).
Google Scholar
Marcandalli, J. et al. Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell 176, 1420–1431.e17 (2019).
Google Scholar
Brouwer, P. J. M. et al. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell 184, 1188–1200.e19 (2021).
Google Scholar
Boyoglu-Barnum, S. et al. Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature 592, 623–628 (2021).
Google Scholar
Maruyama, T. et al. Recombinant human monoclonal antibodies to Ebola virus. J. Infect. Dis. 179, S235–S239 (1999).
Google Scholar
Pettitt, J. et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci. Transl. Med. 5, 199ra113–199ra113 (2013).
Google Scholar
Cagigi, A. et al. Vaccine generation of protective ebola antibodies and identification of conserved B-cell signatures. J. Infect. Dis. 218, S528–s536 (2018).
Google Scholar
Rijal, P. et al. Therapeutic monoclonal antibodies for Ebola virus infection derived from vaccinated humans. Cell Rep. 27, 172–186.e7 (2019).
Google Scholar
He, L. et al. Single-component multilayered self-assembling nanoparticles presenting rationally designed glycoprotein trimers as Ebola virus vaccines. Nat. Commun. 12, 2633 (2021).
Google Scholar
Jones, S. M. et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11, 786–790 (2005).
Google Scholar
Marzi, A. et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc. Natl Acad. Sci. USA 110, 1893–1898 (2013).
Google Scholar
Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet 389, 505–518 (2017).
Google Scholar
Mutua, G. et al. Safety and immunogenicity of a 2-dose heterologous vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Nairobi, Kenya. J. Infect. Dis. 220, 57–67 (2019).
Google Scholar
Ledgerwood, J. E. et al. Chimpanzee adenovirus vector Ebola vaccine. N. Engl. J. Med. 376, 928–938 (2017).
Google Scholar
Thi, E. P. et al. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature 521, 362–365 (2015).
Google Scholar
Elek, S. & Stern, H. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 303, 1–5 (1974).
Google Scholar
Plotkin, S. A., Furukawa, T., Zygraich, N. & Huygelen, C. Candidate cytomegalovirus strain for human vaccination. Infect. Immun. 12, 521–527 (1975).
Google Scholar
Plotkin, S. A. et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 58, 1176–1178 (1994).
Google Scholar
Nelson Cody, S. et al. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. Proc. Natl Acad. Sci. USA 115, 6267–6272 (2018).
Google Scholar
Pass, R. F. et al. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med. 360, 1191–1199 (2009).
Google Scholar
Griffiths, P. D. et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 377, 1256–1263 (2011).
Google Scholar
Liu, Y. et al. Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion. Sci. Adv. 7, eabf3178 (2021).
Google Scholar
Wang, D. & Shenk, T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc. Natl Acad. Sci. USA 102, 18153–18158 (2005).
Google Scholar
Lilleri, D. et al. Human cytomegalovirus (HCMV)-specific T cell but not neutralizing or IgG binding antibody responses to glycoprotein complexes gB, gHgLgO, and pUL128L correlate with protection against high HCMV viral load reactivation in solid-organ transplant recipients. J. Med. Virol. 90, 1620–1628 (2018).
Google Scholar
Hai, R. et al. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J. Virol. 86, 5774–5781 (2012).
Google Scholar
Krammer, F., Pica, N., Hai, R., Margine, I. & Palese, P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87, 6542–6550 (2013).
Google Scholar
Margine, I. et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J. Virol. 87, 10435–10446 (2013).
Google Scholar
Krammer, F. et al. Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J. Virol. 88, 3432–3442 (2014).
Google Scholar
Nachbagauer, R. et al. Hemagglutinin stalk immunity reduces influenza virus replication and transmission in ferrets. J. Virol. 90, 3268–3273 (2015).
Google Scholar
Nachbagauer, R. et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat. Med. 27, 106–114 (2021).
Google Scholar
Kanekiyo, M. et al. Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nat. Immunol. 20, 362–372 (2019).
Google Scholar
Lu, Y., Welsh, J. P. & Swartz, J. R. Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc. Natl Acad. Sci. USA 111, 125–130 (2014).
Google Scholar
Bommakanti, G. et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc. Natl Acad. Sci. USA 107, 13701–13706 (2010).
Google Scholar
Corbett, K. S. et al. Design of nanoparticulate group 2 influenza virus hemagglutinin stem antigens that activate unmutated ancestor B cell receptors of broadly neutralizing antibody lineages. mBio https://doi.org/10.1128/mBio.02810-18 (2019).
Darricarrère, N. et al. Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.abe5449 (2021).
van der Lubbe, J. E. M. et al. Mini-hemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge. NPJ Vaccin. 3, 25 (2018).
Google Scholar
Andrews, S. F. et al. A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination. Nat. Med. 28, 373–382 (2022).
Google Scholar
Houser, K. V. et al. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nat. Med. 28, 383–391 (2022).
Google Scholar
Tseng, Y. C. et al. Egg-based influenza split virus vaccine with monoglycosylation induces cross-strain protection against influenza virus infections. Proc. Natl Acad. Sci. USA 116, 4200–4205 (2019).
Google Scholar
Weidenbacher, P. A. & Kim, P. S. Protect, modify, deprotect (PMD): a strategy for creating vaccines to elicit antibodies targeting a specific epitope. Proc. Natl Acad. Sci. USA 116, 9947–9952 (2019).
Google Scholar
Eggink, D., Goff, P. H. & Palese, P. Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain. J. Virol. 88, 699–704 (2014).
Google Scholar
Kirchdoerfer, R. N. et al. Pre-fusion structure of a human coronavirus spike protein. Nature 531, 118–121 (2016).
Google Scholar
Pallesen, J. et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl Acad. Sci. USA 114, E7348–E7357 (2017).
Google Scholar
Walls, A. C. et al. Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature 531, 114–117 (2016).
Google Scholar
Sadarangani, M., Marchant, A. & Kollmann, T. R. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat. Rev. Immunol. 21, 475–484 (2021).
Google Scholar
Amanat, F. et al. Introduction of two prolines and removal of the polybasic cleavage site lead to higher efficacy of a recombinant spike-based SARS-CoV-2 vaccine in the mouse model. mBio 12, e02648–02620 (2021).
Google Scholar
Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020).
Google Scholar
Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292.e286 (2020).
Google Scholar
Haynes, B. F., Burton, D. R. & Mascola, J. R. Multiple roles for HIV broadly neutralizing antibodies. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aaz2686 (2019).
Sok, D. & Burton, D. R. Recent progress in broadly neutralizing antibodies to HIV. Nat. Immunol. 19, 1179–1188 (2018).
Google Scholar
Caskey, M., Klein, F. & Nussenzweig, M. C. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nat. Med. 25, 547–553 (2019).
Google Scholar
Ferrari, G. et al. Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection. Nat. Rev. Drug Discov. 15, 823–834 (2016).
Google Scholar
Derking, R. & Sanders, R. W. Structure-guided envelope trimer design in HIV-1 vaccine development: a narrative review. J. Int. AIDS Soc. 24, e25797 (2021).
Google Scholar
McGuire, A. T. Targeting broadly neutralizing antibody precursors: a naïve approach to vaccine design. Curr. Opin. HIV AIDS 14, 294–301 (2019).
Google Scholar
Venkatesen, P. Preliminary phase 1 results from an HIV vaccine candidate trial. Lancet Microbe 2, E95 (2021).
Google Scholar
Jardine, J. G. et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 351, 1458–1463 (2016).
Google Scholar
Sok, D. et al. Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. Science 353, 1557–1560 (2016).
Google Scholar
Crowe, J. E. Jr Human antibodies for viral infections. Annu. Rev. Immunol. https://doi.org/10.1146/annurev-immunol-042718-041309 (2022).
Vellas, C. et al. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies. Clin. Microbiol. Infect. 28, 139.e135–139.e8 (2022).
Google Scholar
Rockett, R. et al. Resistance mutations in SARS-CoV-2 Delta variant after sotrovimab use. N. Engl. J. Med. https://doi.org/10.1056/NEJMc2120219 (2022).
Choi, B. et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N. Engl. J. Med. 383, 2291–2293 (2020).
Google Scholar
Vajda, S., Porter, K. A. & Kozakov, D. Progress toward improved understanding of antibody maturation. Curr. Opin. Struct. Biol. 67, 226–231 (2021).
Google Scholar
Nguyen, D. N. et al. Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency. Nat. Biotechnol. 38, 44–49 (2020).
Google Scholar
Bruel, T. et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat. Med. https://doi.org/10.1038/s41591-022-01792-5 (2022).
Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676–681 (2022).
Google Scholar
Iketani, S. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604, 553–556 (2022).
Google Scholar
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect. Dis. 22, 622–635 (2022).
VanBlargan, L. A. et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat. Med. https://doi.org/10.1038/s41591-021-01678-y (2022).
Self, W. H. et al. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(21)00751-9 (2021).
Sakharkar, M. et al. Prolonged evolution of the human B cell response to SARS-CoV-2 infection. Sci. Immunol. 6, eabg6916 (2021).
Google Scholar
Schirrmann, T., Meyer, T., Schütte, M., Frenzel, A. & Hust, M. Phage display for the generation of antibodies for proteome research, diagnostics and therapy. Molecules 16, 412–426 (2011).
Google Scholar
Zurawski, D. V. & McLendon, M. K. Monoclonal antibodies as an antibacterial approach against bacterial pathogens. Antibiotics https://doi.org/10.3390/antibiotics9040155 (2020).
Mohamed, N. et al. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect. Immun. 73, 795–802 (2005).
Google Scholar
Wilcox, M. H. et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N. Engl. J. Med. 376, 305–317 (2017).
Google Scholar
Source: www.nature.com